☰
✕

Meningitis vaccines market

Meningitis Vaccines Market, by Vaccine (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine, Meningococcal Vaccine, and Others), by Age Group (Infants and Adults), by Distribution Channel (Government and Private), and by Country (Egypt, Nigeria, Morocco, Indonesia, Bangladesh, Malaysia, United Arab Emirates, Saudi Arabia, Pakistan, Turkey, Kazakhstan, Jordan, Qatar, Sudan, Lebanon, Uganda, Benin, Cameroon, Gabon, Cote d’Ivoire, Vietnam, Singapore, Mexico, Argentina, Thailand, Philippines, Nepal, Myanmar, and Rest of the World) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample
  • Jun 2022
  • CMI5042
  • 359 Pages
  • Excel & Pdf
  • Pharmaceutical

Meningitis is a rare infection that affects the delicate membranes that surround the brain and spinal cord, known as meninges. The bacteria that cause meningitis can spread when people infected with meningitis cough or sneeze. Meningococcal meningitis is a type of bacterial meningitis caused by the bacterium Neisseria meningitidis. Bacterial meningitis can occur at any age. Infants, on the other hand, are at a larger risk of developing bacterial meningitis

Global meningitis vaccines market is estimated to be valued at US$ 4,070.1 million in 2022 and is expected to exhibit a CAGR of 6.4% during the forecast period (2022-2030).

Figure 1.Global Meningitis Vaccines Market Share (%) in Terms of Value, by Vaccine, 2022

Rise in the incidence of meningitis is expected to drive growth of the meningitis vaccines market

A rise in the incidence of meningitis is expected to increase the demand for meningitis vaccines, thus driving growth of the global meningitis vaccines market. For instance, according to data published by Elsevier Inc., the Netherlands-based academic publishing company, in April 2021, more than 2.5 million cases and 236,000 deaths due to meningitis were reported in 2019 globally .

Meningitis Vaccines Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 4,070.1 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 6.4% 2030 Value Projection: US$ 6,669.3 Mn
Geographies covered:
  • Countries: Egypt, Nigeria, Morocco, Indonesia, Bangladesh, Malaysia, United Arab Emirates, Saudi Arabia, Pakistan, Turkey, Kazakhstan, Jordan, Qatar, Sudan, Lebanon, Uganda, Benin, Cameroon, Gabon, Cote d’Ivoire, Vietnam, Singapore, Mexico, Argentina, Thailand, Philippines, Nepal, Myanmar, Rest of the World
Segments covered:
  • By Vaccine: Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine, Meningococcal Vaccine, Others
  • By Age Group: Infants, Adults
  • By Distribution Channel: Government, Private 
Companies covered:

GlaxoSmithKline plc., Sanofi S.A., Merck & Co., Inc., Pfizer Inc., Novartis AG, Walvax Biotechnology Co., Ltd.,  Incepta Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd., Vacsera, Zhi Fei Biological, BIO MED, Chengdu Kanghua Biological Products, Bharat Biotech., LG Chem, Espromed Bio, Panacea Biotec Limited, Sinovac Biotech Co., Ltd., CanSinoBIO, and Eubiologics Co., Ltd.
Growth Drivers:
  • Rise in the incidence of meningitis
  • Increasing initiatives by governments of countries and regulatory authorities to combat the rising prevalence of meningitis
  • Increasing product launches and approvals
Restraints & Challenges:
  • Product recalls
  • High cost associated with meningitis vaccine

Figure 2.Global Meningitis Vaccines Market Share (%), by Age Group, 2022

Increasing initiatives by governments of countries and regulatory authorities to combat the rising prevalence of meningitis are expected to drive market growth during the forecast period.

Increasing initiatives by governments of countries and regulatory authorities to combat the increasing prevalence of meningitis are expected to propel growth of the global meningitis vaccines market over the forecast period. For instance, in September 2021, the World Health Organization (WHO) and its partners launched the first ever global strategy, Global Roadmap to Defeat Meningitis by 2030, to defeat meningitis. The goal of the strategy is to eliminate epidemics of bacterial meningitis and reduce deaths by 70% and halve the number of cases by 2030.

Global Meningitis Vaccines Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of products, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, faced problems with regard to the transportation of products from one place to another.

The COVID-19 pandemic had a negative economic impact on the global meningitis vaccines market, owing to decrease in vaccination rates for meningitis. For instance, according to an article published by Elsevier B.V., a Netherlands-based academic publishing company specializing in scientific, technical, and medical content, in April 2022, the number of meningococcal C (Men-C) conjugate vaccine doses administered from March 2019 to December 2020 was analyzed in Brazil. In total, 14,832,054 meningococcal C conjugate vaccine doses were administered throughout the investigated period; 66.30% of them from March 2019 to February 2020, and 33.70%, from March 2020 to December 2020. Thus, the COVID-19 pandemic had a negative impact on the number of meningitis vaccine doses administered in the North and South regions (26.98% and 41.47%, respectively) and in eleven states of Brazil

Thus, due to the decreased vaccination rates, the COVID-19 pandemic had a negative economic impact on the global meningitis vaccines market

Global Meningitis Vaccines Market: Restraint

The major factors that are expected to hinder growth of the global meningitis vaccines market include product recalls and high cost associated with meningitis vaccine. For instance, in 2018, The Johns Hopkins University researchers had calculated that requiring all college students to be vaccinated against meningitis B would not be cost-effective. Researchers found that the universal immunization against serogroup B of meningococcal disease, or meningitis B, for college-aged students would only be beneficial if the vaccine costs less than US$ 65. The average price for it is US$ 324.

Key Players

Major players operating in the global meningitis vaccines market include GlaxoSmithKline plc., Sanofi S.A., Merck & Co., Inc., Pfizer Inc., Novartis AG, Walvax Biotechnology Co., Ltd.,  Incepta Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd., Vacsera, Zhi Fei Biological, BIO MED, Chengdu Kanghua Biological Products, Bharat Biotech., LG Chem, Espromed Bio, Panacea Biotec Limited, Sinovac Biotech Co., Ltd., CanSinoBIO, and Eubiologics Co., Ltd.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Vaccine
      • Market Snapshot, By Age Group
      • Market Snapshots, By Distribution Channel
      • Market Snapshot, By Country
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • Epidemiology
    • Vaccine Development Cycle
    • Vaccine Types/Technology and Route of Administration
    • Pricing Analysis
    • Pipeline Analysis
    • Brand Comparison Mapping
  4. Global Meningitis Vaccines Market - Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Demand and Supply Analysis
  5. Global Meningitis Vaccines Market, By Vaccine, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Pneumococcal Conjugate Vaccine
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Pneumococcal Polysaccharide Vaccine  
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Meningococcal Vaccine  
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Others
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  6. Global Meningitis Vaccines Market, By Age Group, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Infants
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Adults
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  7. Global Meningitis Vaccines Market, By Distribution Channel, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Government
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Private
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  8. Global Meningitis Vaccines Market, By Country, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, By Country, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, For Countries, 2018–2030
      • Country Trends
    • Egypt
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Nigeria
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Morocco
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Indonesia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Bangladesh
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Malaysia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • United Arab Emirates
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Saudi Arabia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Pakistan
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Turkey
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Kazakhstan
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Jordan
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Qatar
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Sudan
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Lebanon
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Uganda
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Benin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Cameroon
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Gabon
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Cote d’Ivoire
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Vietnam
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Singapore
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Mexico
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Argentina
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Thailand
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Philippines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Nepal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Myanmar
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Rest of the World
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Vaccine, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  9. Competitive Landscape
    • GlaxoSmithKline plc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sanofi S.A.    
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck & Co., Inc.  
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer Inc.  
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Walvax Biotechnology Co., Ltd.  
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Incepta Pharmaceuticals Ltd.  
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Serum Institute of India Pvt. Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Vacsera  
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Zhi Fei Biological
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • BIO MED
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Chengdu Kanghua Biological Products
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bharat Biotech.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • LG Chem
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Espromed Bio
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Panacea Biotec Limited
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sinovac Biotech Co., Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • CanSinoBIO
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Eubiologics Co., Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
  10. Section
    • Research Methodology
    • About Us

*Browse 98 market data tables and 45 figures on "Meningitis Vaccines Market” - Global forecast to 2030

Detailed Segmentation:

  • Global Meningitis Vaccines Market, By Vaccine:
    • Pneumococcal Conjugate Vaccine
    • Pneumococcal Polysaccharide Vaccine 
    • Meningococcal Vaccine 
    • Others 
  • Global Meningitis Vaccines Market, By Age Group:
    • Infants
    • Adults
  • Global Meningitis Vaccines Market, By Distribution Channel:
    • Government
    • Private
  • Global Meningitis Vaccines Market, By Country:
    • Egypt
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others   
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Nigeria
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Morocco
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Indonesia
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Bangladesh
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Malaysia
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • United Arab Emirates
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Saudi Arabia
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Pakistan
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Turkey
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Kazakhstan
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Jordan
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Qatar
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Sudan
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Lebanon
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Uganda
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Benin
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Cameroon
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Gabon
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Cote d’Ivoire
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Vietnam
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Singapore
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Mexico
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Argentina
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Thailand
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Philippines
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Nepal
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Myanmar
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine  
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
        • Private
    • Rest of the World
      • By Vaccine
        • Pneumococcal Conjugate Vaccine
        • Pneumococcal Polysaccharide Vaccine 
        • Meningococcal Vaccine 
        • Others  
      • By Age Group
        • Infants
        • Adults
      • By Distribution Channel
        • Government
            • Private
- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global meningitis vaccines market during the forecast period (2022-2030)?

Global meningitis market size is estimated to be valued at US$ 4,070.1 million in 2022 and is expected to exhibit a CAGR of 6.4% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as rise in the incidence of meningitis, increasing initiatives by governments of countries and regulatory authorities to combat the rising prevalence of meningitis, and increasing product launches and approvals are expected to drive the market  growth.

Which is the leading vaccine segment in the market?

Pneumococcal Conjugate Vaccine segment is the leading vaccine segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include product recalls and high cost associated with meningitis vaccine.

Which are the major players operating in the market?

Major players operating in the market include GlaxoSmithKline plc., Sanofi S.A., Merck & Co., Inc., Pfizer Inc., Novartis AG, Walvax Biotechnology Co., Ltd., Incepta Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd., Vacsera, Zhi Fei Biological, BIO MED, Chengdu Kanghua Biological Products, Bharat Biotech., LG Chem, Espromed Bio, Panacea Biotec Limited, Sinovac Biotech Co., Ltd., CanSinoBIO, and Eubiologics Co., Ltd.
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Buy Now with Special Discount
Customize Now